High Myostatin Serum Related with High Prevalence of Sarcopenia Among Elderly Population in Pedawa Village, Bali, Indonesia

I Gusti Putu Suka Aryana, I Nyoman Astika, Raden Ayu Tuty Kuswardhani, Ida Bagus Putu Putrawan, Ni Ketut Rai Purnami, Wayan Giri Putra, Anak Agung Wiradewi Lestari, I Nyoman Wande

Abstract


BACKGROUND: Sarcopenia is defined as a decrease in muscle mass accompanied by a decrease in muscle strength and performance. Sarcopenia arises from the disruption of the complex balance between anabolic and catabolic factors. Myostatin strongly influences muscle growth inhibition. Deletion and function loss of myostatin causes hyperplasia and skeletal muscle hypertrophy.

METHODS: This study was an analytical cross-sectional study. Seventy respondents aged ≥60 years in Pedawa Village, Bali, Indonesia were selected by using the stratified random sampling technique. Sarcopenia status was assessed according to Asian Working Group for Sarcopenia (AWGS) criteria, including muscle mass, grip strength, and walking speed. While the myostatin serum levels was measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS: The incidence of sarcopenia in the elderly was 45 people (64.3%). Based on the analysis, there was a significant difference between myostatin levels in sarcopenia subjects (47.59 ng/mL) and non-sarcopenia subjects (39.7 ng/mL). Based on the statistical calculations, it was determined that the cut-off range of myostatin levels was 48.91 ng/mL. The prevalence ratio of sarcopenia incidence based on the myostatin levels in the elderly was 3.84, while based on the combination of age risk and myostatin levels was 9.75.

CONCLUSION: Based of the data, there are significant differences of myostatin level between elderly people with and without sarcopenia. The prevalence of high myostatin levels in elderly is almost 4 times higher than low myostatin levels in the elderly.

KEYWORDS: myostatin, sarcopenia, elderly


Full Text:

PDF

References


National Institute on Aging, National Institutes of Health, US Department of Health and Human Services. Global Health and Aging. Geneva: World Health Organization; 2011, article.

Kirkwood TBL. A systematic look at an old problem. Nature. 2008; 451: 644-7, CrossRef.

Arnold A, Egger A, Handschin C. PGC-1 α and myokines in the aging muscle – a mini-review. Gerontology. 2011; 57: 37-43, CrossRef.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010; 39: 412-23, CrossRef.

Kim T, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab. 2013; 20: 1-10, CrossRef.

White TA, Lebrasseur K. Myostatin and sarcopenia: opportunities and challenges – a mini-review. Gerontology. 2014; 60(4): 289-93, CrossRef.

Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002; 277: 49831-40, CrossRef.

Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor. J Biol Chem. 2007; 282: 3799-808, CrossRef.

Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol. 2009; 296: C1248-57, CrossRef.

Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. AJP Cell Physiol. 2009; 296: C1258-70, CrossRef.

Murbawani EA, Puruhita N, Yudomurti. Tinggi badan yang diukur dan berdasarkan tinggi lutut menggunakan rumus Chumlea pada lansia. Med Med Indones. 2012; 49: 1-6, article.

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 2014; 15: 95-101, CrossRef.

Vitriana, Defi IR, Irawan GN, Setiabudiawan B. Prevalensi sarkopenia pada lansia di komunitas (Community Dwelling) berdasarkan dua nilai cut-off parameter diagnosis. Maj Kedokt Bandung. 2016; 48: 164-70, article.

Limpawattana P, Kotruchin P, Pongchaiyakul C. Sarcopenia in Asia. Osteoporos Sarcopenia. 2015; 1: 92-7, CrossRef.

Gao L, Jiang J, Yang M, Hao Q, Luo L, Dong B. Prevalence of sarcopenia and associated factors in Chinese community-dwelling elderly: comparison between rural and urban areas. J Am Med Dir Assoc. 2015; 16: 1003.e1-e6, CrossRef.

Messier V, Rabasa-lhoret R, Barbat-artigas S, Elisha B, Karelis AD, Aubertin-leheudre M. Menopause and sarcopenia: a potential role for sex hormones. Maturitas. 2011; 68: 331-6, CrossRef.

Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993; 84: 95-8, CrossRef.

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147: 755-63, CrossRef.

Fried LP, Walston JD, Ferrucci L. Frailty. In: Geriatric Medicine. 6th ed. Berlin: Springer-Verlag; 2009. p.1067–76, CrossRef.

Bergen HR, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometrybased assay. Skelet Muscle. 2015; 5: 21, CrossRef.

Siriett V, Platt L, Salerno MS, Ling N, Kambadur R, Sharma M. Prolonged absence of myostatin reduces sarcopenia. J Cell Physiol. 2006; 209: 866-73, CrossRef.

Camporez JG, Petersen MC, Abudukadier A, Moreira G V, Jurczak MJ, Friedman G, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA.2016; 113: 2212-7, CrossRef.

Peng LN, Lee WJ, Liu LK, Lin MH, Chen LK. Healthy communityliving older men differ from women in associations between myostatin levels and skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2018; 9: 635-42, CrossRef.

Elkina Y, Haehling S Von, Anker SD. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011; 2: 143-51, CrossRef.

Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol. 2012; 2012: 127362, CrossRef.




DOI: https://doi.org/10.18585/inabj.v11i3.822

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute